Preoperative CT-scan-based sizing and in-stent restenosis in peripheral endovascular revascularizations

Abstract

Objectives

This study evaluates the effect of stent sizing with CT-scan on the incidence of restenosis in peripheral arterial disease.

Methods

This retrospective study included 59 patients with 66 arterial lesions who underwent a endovascular procedure for peripheral arterial disease between April 2013 and October 2013. All patients had de novo iliac or femoral lesions, were candidates for an endovascular procedure alone and underwent CTA preoperatively. The stent actually implanted, whose dimensions were chosen on the basis of the operator’s experience on an intraoperative 2D angiography, was compared to the “ideal” stent chosen retrospectively on the basis of precise lesion sizing by the preoperative CTA. Planning was considered “discordant” if there was a difference in length of more than 20 mm and/or a difference in diameter of more than 1 mm between the ideal stent and the actual stent.

Results

For iliac lesions, discordance essentially concerned stent diameter (36.1%), whereas stent length was the main reason for discordance for femoral lesions (36.7%). The median length of follow-up was 18 months (range 6–24). For iliac lesions, freedom from restenosis at 24 months was higher for patients with concordant planning (90% vs. 62.5%, p = 0.045). Most restenoses occurred in the external iliac artery, where there was a tendency towards oversizing of the implanted stent. For femoral lesions, the restenosis-free rate at 24 months was higher for patients with concordant planning (77.8% vs. 50%, p = 0.057). A multivariate analysis was conducted on the prediction of restenosis. Among factors, only discordant planning was found to be a significant predictor of restenosis with an odds ratio of 0.115 (95% confidence interval, 0.02–0.674; p = 0.016).

Conclusion

The absence of sizing for peripheral lesions engenders a tendency to choose the wrong stent, in particular in terms of diameter in iliac arteries and length in femoral arteries.

Keywords

Sizing peripheral arterial disease in-stent restenosis stent endovascular femoral atherosclerosis

Get full access to this article

View all access options for this article.

References

Dick

Wallner

Sabeti

et al.

Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheterization Cardiovasc Intervention 2009; 74: 1090–1095.

Laird

Katzen

Scheinert

et al.

Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results From the RESILIENT Randomized Trial. Circulat: Cardiovasc Intervention 2010; 3: 267–276.

Schillinger

Sabeti

Loewe

et al.

Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006; 354: 1879–1888.

Hoffmann

Mintz

Dussaillant

et al.

Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996; 94: 1247–1254.

Saguner

Traupe

Raber

et al.

Oversizing and restenosis with self-expanding stents in iliofemoral arteries. Cardiovasc Intervent Radiol 2012; 35: 906–913.

Yamaguchi

Sugimoto

Zamora

et al.

Placement of self-expanding stents with different diameters in the porcine venous system: an experimental study. J Vasc Intervention Radiol 2006; 17: 113–119.

Zhao

Nikanorov

Virmani

et al.

Late stent expansion and neointimal proliferation of oversized nitinol stents in peripheral arteries. Cardiovasc Intervention Radiol 2009; 32: 720–726.

Kaladji

Lucas

Kervio

et al.

Sizing for endovascular aneurysm repair: clinical evaluation of a new automated three-dimensional software. Ann Vasc Surg 2010; 24: 912–920.

Marzelle JBF, Fallouh A, Parot A, et al. Techniques de base en chirurgie endovasculaire. EMC (Elsevier Masson SAS, Paris), Techniques chirurgicales - Chirurgie vasculaire,43-012, 2007.

10.

Lugmayr

Holzer

Kastner

et al.

Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: a midterm follow-up. Radiology 2002; 222: 37–43.

11.

Davaine

Azema

Guyomarch

et al.

One-year clinical outcome after primary stenting for Trans-Atlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions (the STELLA “STEnting Long de L’Artere femorale superficielle” cohort). Eur J Vasc Endovasc Surg 2012; 44: 432–441.

12.

Farb

Sangiorgi

Carter

et al.

Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44–52.

13.

Saxon

Chervu

Jones

et al.

Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. J Vasc Interv Radiol 2013; 24: 165–173; quiz 74.

14.

Sobocinski

Chenorhokian

Maurel

et al.

The benefits of EVAR planning using a 3D workstation. Eur J Vasc Endovasc Surg 2013; 46: 418–423.

15.

Becquemin

Favre

Marzelle

et al.

Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. J Vasc Surg 2003; 37: 487–494.

16.

Cejna

Thurnher

Illiasch

et al.

PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol 2001; 12: 23–31.

17.

Grimm

Muller-Hulsbeck

Jahnke

et al.

Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol 2001; 12: 935–942.

18.

Muradin

Bosch

Stijnen

et al.

Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology 2001; 221: 137–145.

19.

Saxon

Coffman

Gooding

et al.

Long-term results of ePTFE stent-graft versus angioplasty in the femoropopliteal artery: single center experience from a prospective, randomized trial. J Vasc Interv Radiol 2003; 14: 303–311.

20.

Duda

Bosiers

Lammer

et al.

Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005; 16: 331–338.

21.

Lammer

Bosiers

Zeller

et al.

First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg 2011; 54: 394–401.

22.

Azaouzi

Lebaal

Makradi

et al.

Optimization based simulation of self-expanding Nitinol stent. Mater Des 2013; 50: 917–928.

23.

Azaouzi

Makradi

Belouettar

. Deployment of a self-expanding stent inside an artery: a finite element analysis. Mater Des 2012; 41: 410–420.

24.

Pelton

Schroeder

Mitchell

et al.

Fatigue and durability of nitinol stents. J Mech Behav Biomed Mater 2008; 1: 153–64.

25.

Ren

Wang

Morgan

et al.

Protein kinase C-delta (PKCdelta) regulates proinflammatory chemokine expression through cytosolic interaction with the NF-kappaB subunit p65 in vascular smooth muscle cells. J Biol Chem 2014; 289: 9013–9026.

26.

Ren

Wang

et al.

Protein kinase C-delta mediates adventitial cell migration through regulation of monocyte chemoattractant protein-1 expression in a rat angioplasty model. Arterioscler Thromb Vasc Biol 2012; 32: 943–954.

27.

Phillips

Ansel

. Femoropopliteal in-stent restenosis: review and potential for drug based therapy. J Cardiovasc Surg (Torino) 2013; 54: 333–336.

28.

Ballyk

. Intramural stress increases exponentially with stent diameter: a stress threshold for neointimal hyperplasia. J Vasc Interv Radiol 2006; 17: 1139–1145.

29.

Laird

Katzen

Scheinert

et al.

Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther 2012; 19: 1–9.